Anbio Biotechnology (NNNN) vs Sanara MedTech (SMTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sanara MedTech (SMTI) has outperformed Anbio Biotechnology (NNNN) over the past year, gaining 10.9% versus a loss of 84.3%. Sanara MedTech is the larger company by market cap ($322.2 million vs $204.5 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNNN | SMTI |
|---|---|---|
| Share price | $4.66 | $35.07 |
| Market cap | $204.53M | $322.22M |
| 1-day change | +0.87% | +0.06% |
| YTD return | -84.50% | +50.19% |
| 1-year return | -84.25% | +10.95% |
| 5-year return | — | +6.34% |
| P/E ratio (TTM) | 31.07 | — |
| Forward P/E | — | 64.94 |
| EPS (TTM) | $0.15 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $44.73 | $35.34 |
| 52-week low | $4.20 | $16.05 |
| Distance from 52-week high | -89.58% | -0.76% |
| Analyst consensus | — | none |
| Avg. price target upside | — | -0.20% |
| Average volume | 146.84K | 280.40K |
| Shares outstanding | 43.89M | 9.19M |
| Employees | 27 | 108 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SMTI has outperformed NNNN by 95.2 percentage points over the past year.
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
About Sanara MedTech
SMTI stock →Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns.
Health Care · Industrial Specialties · 108 employees
NNNN vs SMTI FAQ
Which is bigger, Anbio Biotechnology or Sanara MedTech?
Sanara MedTech (SMTI) is larger, with a market capitalization of $322.22M compared with $204.53M for Anbio Biotechnology (NNNN).
Which stock has performed better over the past year, NNNN or SMTI?
SMTI returned +10.95% over the past 12 months, compared with -84.25% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Are Anbio Biotechnology and Sanara MedTech in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Anbio Biotechnology and Industrial Specialties for Sanara MedTech.